Volume 69, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


The sporontocidal activity of tafenoquine (WR-238605) and artelinic acid was determined against naturally circulating isolates of in western Thailand. Primaquine was used as a negative control and a dihydroacridine-dione (WR-250547) was used as a positive control. Laboratory-reared mosquitoes were infected with by allowing mosquitoes to feed on blood (placed in an artificial-membrane feeding apparatus) collected from gametocytemic volunteers reporting to local malaria clinics in Tak province, Thailand. Four days post-infection, mosquitoes were refed on uninfected mice treated 90 minutes earlier with a given drug. Drug activity was determined by assessing oocyst and sporozoite development. Neither primaquine nor artelinic acid affected oocyst or sporozoite development at a dose of 100 mg of base drug/kg of mouse body weight. In contrast, tafenoquine and WR-250547 affected sporogonic development at doses as low as 25.0 and 0.39 mg/kg, respectively. The potential role of these compounds in the prevention of malaria transmission is discussed, as are alternative strategies for the use of transmission-blocking antimalarial drugs.


Article metrics loading...

Loading full text...

Full text loading...



  1. World Health Organization, 1987. The Biology of Malaria Parasites. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 743. Geneva.
  2. Gilles HM, Warrell DA, 1993. Bruce-Chwatt’s Essential Malariology. Third edition. London: Edward Arnold, 164–195.
  3. Oaks SC, Mitchell VS, Pearson GW, Carpenter CCJ, 1991. Malaria: Obstacles and Opportunities. Washington: National Academy Press.
  4. Coleman RE, Ponsa N, Eikarat N, Kollars TM Jr, Sattabongkot J, 2001. Prevention of sporogony of Plasmodium vivax in Anopheles dirus mosquitoes by transmission-blocking antimalarials. Am J Trop Med Hyg 65 : 214–218.
  5. Coleman RE, Nath AK, Schneider I, Song G-H, Klein TA, Milhous WK, 1994. Transmission-blocking antimalarials prevent sporogony of Plasmodium falciparum and P. berghei in Anopheles stephensi mosquitoes. Am J Trop Med Hyg 50 : 646–653.
  6. Coleman RE, Clavin AM, Milhous WK, 1992. Gametocytocidal and sporontocidal activity of antimalarials against Plasmodium berghei ANKA in ICR mice and Anopheles stephensi mosquitoes. Am J Trop Med Hyg 46 : 169–182.
  7. Coleman RE, 1990. Sporontocidal activity of the antimalarial WR-238605 against Plasmodium berghei ANKA in Anopheles stephensi. Am J Trop Med Hyg 42 : 196–205.
  8. Butcher GA, 1997. Antimalarial drugs and the mosquito transmission of Plasmodium. Int J Parasitol 27 : 975–987.
  9. Teklehaimanot A, Nguyen-Dinh P, Collins WE, Barber AM, Campbell CC, 1985. Evaluation of sporontocidal compounds using Plasmodium falciparum gametocytes produced in vitro. Am J Trop Med Hyg 34 : 429–434.
  10. Coleman RE, Maneechai N, Yim-Amnuaychok N, Kumpitak C, Soyseng V, Miller RS, Thimasarn K, Sattabongkot J, 2002. Field evaluation of the ICT malaria Pf/Pv immunochromatographic test for the detection of asymptomatic malaria in a Plasmodium falciparum/vivax endemic area in Thailand. Am J Trop Med Hyg 66 : 379–383.
  11. Young MD, 1959. The effect of small doses of primaquine upon malaria infections. Indian J Malariol 13 : 69–74.
  12. Brueckner RP, Lasseter KC, Lin ET, Schuster BG, 1998. First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. Am J Trop Med Hyg 58 : 645–649.
  13. Milhous WK, 2001. Development of new drugs for chemoprophylaxis of malaria. Med Trop (Mars) 61 : 48–50.
  14. Peters W, 1999. The evolution of tafenoquine—antimalarial for a new millennium? J R Soc Med 92 : 345–352.
  15. Brueckner RP, Coster T, Wesche DL, Shmuklarsky M, Schuster BG, 1998. Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial. Antimicrob Agents Chemother 42 : 1293–1294.
  16. Lell B, Faucher JF, Missinou MA, Borrmann S, Dangelmaier O, Horton J, Kremsner PG, 2000. Malaria chemoprophylaxis with tafenoquine: a randomised study. Lancet 355 : 2041–2045.
  17. Edstein MD, Walsh DS, Eamsila C, Sasiprapha T, Nasveld PE, Kitchener S, Rieckmann KH, 2001. Malaria prophylaxis/ radical cure: recent experiences of the Australian Defence Force. Med Trop (Mars) 61 : 56–58.
  18. Cooper RD, Milhous WK, Rieckmann KH, 1994. The efficacy of WR 238605 against the blood stages of a chloroquine resistant strain of Plasmodium vivax. Trans R Soc Trop Med Hyg 88 : 691–692.
  19. Peters W, Robinson BL, Milhous WK, 1993. The chemotherapy of rodent malaria. LI. Studies on a new 8-aminoquinoline, WR 238,605. Ann Trop Med Parasitol 87 : 547–552.
  20. Obaldia N III, Rossan RN, Cooper RD, Kyle DE, Nuzum EO, Rieckmann KH, Shanks GD, 1997. WR 238605, chloroquine, and their combinations as blood schizonticides against a chloroquine-resistant strain of Plasmodium vivax in Aotus monkeys. Am J Trop Med Hyg 56 : 508–510.
  21. Tripathi R, Puri SK, Dutta GP, 1996. Sodium β-artelinate—A new potential gametocytocide. Exp Parasitol 82 : 251–254.
  22. Mehra N, Bhasin VK, 1993. In vitro gametocytocidal activity of artemesinin and its derivatives on Plasmodium falciparum. Jpn J Med Sci Biol 46 : 37–43.
  23. Chen PQ, Li GQ, Guo XB, He KR, Fu YX, Fu LC, Song YZ, 1994. The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin. Chin Med J 107 : 709–711.
  24. Price RN, 2000. Artemisinin drugs: novel antimalarial agents. Expert Opin Investig Drugs 9 : 1815–1827.
  25. Labbe AC, Loutfy MR, Kain KC, 2001. Recent advances in the prophylaxis and treatment of Malaria. Curr Infect Dis Rep 3 : 68–76.
  26. Lopez-Antunano FJ, 1999. Is primaquine useful and safe as true exo-erythrocytic merontocidal, hypnozoitocidal and gametocidal antimalarial drug? Salud Publica Mex 41 : 410–419.
  27. Thimasarn K, 1992. Current measures of containment of multi-drug resistant falciparum malaria in Thailand. Southeast Asian J Trop Med Public Health 23 (Suppl 4): 139–142.
  28. Jong EC, Nothdurft HD, 2001. Current drugs for antimalarial chemoprophylaxis: a review of efficacy and safety. J Travel Med 8 (Suppl 3): S48–S56.
  29. Shanks GD, Kain KC, Keystone JS, 2001. Malaria chemoprophylaxis in the age of drug resistance. II. Drugs that may be available in the future. Clin Infect Dis 33 : 381–385.
  30. Kain KC, Shanks GD, Keystone JS, 2001. Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens. Clin Infect Dis 33 : 226–234.
  31. Li QG, Peggins JO, Lin AJ, Masonic KJ, Trotman KM, Brewer TG, 1998. Pharmacology and toxicology of artelinic acid: pre-clinical investigations on pharmacokinetics, metabolism, protein and red blood cell binding, and acute and anorectic toxicities. Trans R Soc Trop Med Hyg 92 : 332–340.
  32. Institute of Medicine, 1991. Malaria: Obstacles and Opportunities. Oaks SC, Mitchell VS, Pearson GW, Carpenter CCJ, eds. Washington, DC: National Academy Press.

Data & Media loading...

  • Received : 31 Oct 2002
  • Accepted : 20 Jan 2003

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error